baloxavir

a selective inhibitor of influenza cap-dependent endonuclease for treatment of influenza A and B virus infections

Also Known As:

(((12aR)-12-((11S)-7,8-difluoro-6,11-dihydrodibenzo(b,E)thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12ahexahydro-1H-(1,4)oxazino(3,4-C)pyrido(2,1-F)(1,2,4)triazin-7-yl)oxy)methyl methyl carbonate; (12aR)-12-((11S)-7,8-difluoro-6,11-dihydrodibenzo(b,e)thiepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1h-(1,4)oxazino(3,4-c)pyrido(2,1-f)(1,2,4)triazine-6,8-dione; Xofluza; baloxavir marboxil

Networked: 207 relevant articles (30 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shishido, Takao: 16 articles (01/2022 - 01/2018)
2.	Takashita, Emi: 14 articles (07/2022 - 01/2018)
3.	Uehara, Takeki: 12 articles (08/2021 - 01/2018)
4.	Fujisaki, Seiichiro: 11 articles (07/2022 - 01/2018)
5.	Ishibashi, Toru: 10 articles (04/2021 - 11/2018)
6.	Hayden, Frederick G: 9 articles (10/2021 - 01/2018)
7.	Tsuchiya, Kenji: 9 articles (08/2021 - 01/2018)
8.	Govorkova, Elena A: 8 articles (01/2022 - 01/2020)
9.	Hirotsu, Nobuo: 8 articles (02/2021 - 01/2018)
10.	Hurt, Aeron C: 8 articles (01/2021 - 01/2018)

Related Diseases

1.	Human Influenza (Influenza) 10/01/2020 - "We aimed to study the efficacy of baloxavir in outpatients at high risk of developing influenza-associated complications. " 10/01/2021 - "The findings of this meta-analysis suggested that baloxavir is superior to placebo in the treatment of influenza in both clinical outcome and virological response. " 01/01/2021 - "Baloxavir was virologically effective for influenza in the clinical setting of the 2019-2020 Japanese season. " 11/01/2020 - "Baloxavir Effective in Preventing Influenza in Household Contacts." 01/01/2022 - "Based on a PK study, clinical data including dosing regimen developed in Japan were adequately extrapolated to Korea, supporting the approval of baloxavir marboxil in Korean as a new treatment option for influenza."
2.	Infections 01/01/2020 - "We found that baloxavir treatment reduced infectious viral shedding in the upper respiratory tract of ferrets compared to placebo, and reduced the frequency of transmission amongst sentinels in both experimental setups, even when treatment was delayed until 2 days post-infection. " 09/01/2020 - "The objective of this study is to describe the effect of baloxavir marboxil in controlling an outbreak of this infection. " 01/01/2020 - "This open-label study administered 1 weight-adjusted dose of baloxavir to 107 children aged 1-11 years with laboratory-confirmed, febrile influenza virus infection of ≤48 hours duration. " 01/01/2023 - "Baloxavir treatment protected mice from lethal infection with wild-type or NA-R152K virus, but failed to protect mice from lethal infection with PA-I38T or PA-I38T/NA-R152K virus. " 12/24/2021 - "Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. "
3.	Hantavirus Infections 01/01/2020 - "Corrigendum: An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection." 01/01/2019 - "An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection."
4.	Body Weight (Weight, Body) 12/21/2021 - "We observed an improved body weight, survival and viral clearance in baloxavir marboxil treated mice. " 01/01/2022 - "This open-label and single-ascending dose study was conducted in 30 Korean male subjects, with a single oral dose of baloxavir marboxil (20, 40, or 80 mg) administered to eight subjects each; additionally, 80 mg was administered to six subjects (body weight >80 kg). " 01/01/2020 - "Daily treatment with a suboptimal dose of baloxavir marboxil increased the survival time of the virus-infected nude mice but did not clear the virus from their respiratory organs, resulting in gradual body weight loss after termination of treatment. " 08/01/2021 - "Patients aged <12 years with confirmed influenza received a single oral dose of baloxavir marboxil at 2 mg/kg if body weight was <10 kg or 20 mg if ≥ 10 to <20 kg. " 01/01/2022 - "Body weight-adjusted analysis revealed that exposure to baloxavir acid did not significantly differ between Korean and Japanese subjects. "
5.	Influenza in Birds (Avian Flu) 01/01/2022 - "Genetic Evolution of Avian Influenza A (H9N2) Viruses Isolated from Domestic Poultry in Uganda Reveals Evidence of Mammalian Host Adaptation, Increased Virulence and Reduced Sensitivity to Baloxavir." 01/01/2022 - "Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection." 11/15/2019 - "Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected with a recent highly pathogenic version of H7N9 human isolates is unknown. " 12/08/2020 - "Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens." 01/01/2021 - "Baloxavir acid (BXA), the active compound of BXM, demonstrated a potent in vitro activity against different types/subtypes of influenza viruses including seasonal influenza A/B strains as well as avian influenza A viruses with a pandemic potential. "

Related Drugs and Biologics

1.	Oseltamivir (Tamiflu)
2.	Neuraminidase (Sialidase)
3.	baloxavir
4.	Antiviral Agents (Antivirals)
5.	Endonucleases
6.	Acids
7.	Enzymes
8.	peramivir
9.	Proteins (Proteins, Gene)
10.	Phosphates (Orthophosphate)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Cell Transplantation
4.	Drug Therapy (Chemotherapy)